TxCell Launches Industrialization Laboratories and Technology Transfer Academy
TxCell’s new facilities are based in Sophia Antipolis, France, on the premises of GenBiotech.
TxCell, a biotechnology company developing personalized cellular immunotherapies using regulatory T-cells to treat chronic inflammatory and autoimmune diseases, announced the launch of its new process industrialization laboratories and technology transfer academy facilities in Sophia Antipolis, France, according to a Feb. 29, 2016 press announcement. The new facilities will be based in Sophia Antipolis, on the premises of GenBiotech, an affiliate company of the Genevrier Laboratories.
According to the company, the facilities will be used to improve the existing TxCell manufacturing process for its ASTrIA platform, as well as development and manufacturing of its ENTrIA platform. The facilities will also host the TxCell Academy for Technology Transfer. The academy will be responsible for educating and training all contract manufacturing partners. It will also train future strategic partners on the manufacturing processes of TxCell’s personalized cellular therapies.
Source: TxCell
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
